-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
4D Molecular Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2019 to 2023.
- 4D Molecular Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $7.29M, a 96% increase year-over-year.
- 4D Molecular Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $24.9M, a 177% increase year-over-year.
- 4D Molecular Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $12M, a 374% increase from 2022.
- 4D Molecular Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $2.54M, a 15763% increase from 2021.
- 4D Molecular Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was $16K.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)